🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📑Risk of HCC ⬇️ in HBV-related patients with cirrhosis acquired recompensation‼️ 🔑 Patients with HBV-related decompensated cirrhosis who experienced recompensation had a ⬇️ risk of HCC comparable to those with compensated cirrhosis #LiverTwitter journals.lww.com/hepcomm/fullte…

📑 Hepatology consultation is associated with ⬇️ early return to 🍷 alcohol use after discharge from an inpatient alcohol use disorder treatment program‼️ #LiverTwitter #LiverX journals.lww.com/hepcomm/fullte…

📑 PNPLA3 risk allele is associated with risk of #HCC but not decompensation in compensated #cirrhosis 🧬 PNPLA3-rs738409-GG variant is associated with 2.4X ⬆️ risk of HCC‼️ #LiverTwitter journals.lww.com/hepcomm/fullte…

Everything you need to know about terlipressin journals.lww.com/hepcomm/fullte…

Original Article Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction Van Kleef et al. #LiverX tinyurl.com/245fzwhb

New Review - Primary biliary cholangitis and the narrowing gap towards optimal disease control thelancet.com/journals/langa… #LiverTwitter #MedTwitter

The 2024 Impact Factors are in, and we have good news! We're proud to share that the Impact Factor for HEPATOLOGY Journal—the leading scientific journal in #liverdisease—increased to 15.8. Check out the top 10 cited articles here: bit.ly/4lBhtw7 #Hepatology #AASLD

Presented at #ADASciSessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body-weight reduction in adults without diabetes and with overweight or obesity. Full trial results: nej.md/444aW7f

Read the #GUTOnline paper by Lai et al on "Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/3FObRzm #MASLD #HCC @hanneshagstrom Grace Wong Grazia Pennisi

Can we⬇️avoidable #readmissions in #cirrhosis? Yes! A multi-center #RCT of #PatientBuddy & #EncephalApp VCU Health Mayo Clinic Gastroenterology & Hepatology & Richmond VAMC 🙏AHRQ 🔑Diff practice types 🔑464 subjects (w caregivers) 🔑Freely available Apps HEPATOLOGY Journal ⤵️ journals.lww.com/hep/abstract/9…

The authors in today’s #readoftheweek📚 evaluated the prognostic relevance of residual ascites grades in patients with advanced chronic liver disease after #TIPS placement. Read here this JHEP Reports article: jhep-reports.eu/article/S2589-… 🙏 Lukas Hartl, Mathias Jachs, Anja Tiede,

🔥Hot Topic in Liver Transplantation Journal (LTxJournal)! Have a patient with decompensated #cirrhosis and low MELD scores? This review highlights: 📌 the of limits MELD-based allocation 📌 newer scoring models 📌 management of complications and timely transplant referral. bit.ly/3TLDfB2

🚀Our latest study on FIB-4 and LSM-VCTE guided risk-based #HCC #surveillance for patients with #MASLD 🔗shorturl.at/EmbgF Huge thanks to #VCTE Prognosis Group collaborators! #NIT #FIB4 #LSM Gut Journal CUHK Gastroenterology & Hepatology CUHK Medicine Jimmy Che-To Lai Grace Wong Vincent Wong

Original Article Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design Brookhart et al. #LiverX tinyurl.com/mr44a5xh

On-demand TACE + with Atezo+Bev or TACE alone in intermediate-to-high burden HCC 🔎TALENTACE phase III 👉ORR 49 vs 34% 👉mPFS 11.3 vs 7.03 👉mOS 34 vs 25 mo 🧐 In line with LEAP-12 & EMERALD-1, still no mature OS data, supportive #ESMOAmbassadors #ESMOGI25 ESMO - Eur. Oncology

Grade 1 ascites is not trivial journals.lww.com/hep/abstract/9…

Drs. @LorenzBALCAR of MedUni Wien & Marta Tonon identify a #cirrhosis population with #ascites at particular risk for short-term #PortalHypertension complications JHEP Reports t.ly/iCvXY Ascites #Grade3 + 🚨MELD ≥12 or 🚨Na ≤135 ➡️ good candidates for #TIPS

I regret to inform you that rifaximin did not improve survival in this RCT enrolling patients with cirrhosis and ascites

REMEMBERING Professor JAUME BOSCH (jaumebosch) President of Baveno The Baveno Cooperation: an EASL Consortium Friend and Mentor to many

CIRROXABAN Study is finally here! 🔬 First DB RCT evaluating rivaroxaban in cirrhosis 💡 Complication-free survival benefit in Child‑Pugh B7 (HR 0.26 [95 % CI 0.07–0.90]). ⚠️ Mild bleeding ↑, but no increase in severe events. 📄 journal-of-hepatology.eu/article/S0168-…